Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: BIBR 1017 BS powder
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02184338
Bioavailability of Two Sustained-release Theophylline Products in Healthy Males
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: anhydrous theophylline, 350 mgDrug: anhydrous theophylline, 300 mg
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT02184247
Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children Undergoing Minor Surgery
Phase 4
Completed
- Conditions
- Pain
- Interventions
- Drug: Magnesium metamizolDrug: Placebo
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 122
- Registration Number
- NCT02184273
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 19
- Registration Number
- NCT02184078
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
Phase 3
Completed
- Conditions
- Candidiasis, Oral
- Interventions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 187
- Registration Number
- NCT02184351
Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)
Phase 4
Completed
- Conditions
- Venous Insufficiency
- Interventions
- Drug: Antistax film coated tablets
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT02184234
Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 138
- Registration Number
- NCT02184299
Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints
Phase 3
Completed
- Conditions
- Menopause
- Interventions
- Drug: Oestrofeminal®Drug: High dose of Klimadynon®Drug: PlaceboDrug: Medium dose of Klimadynon®Drug: Low dose of Klimadynon®
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 161
- Registration Number
- NCT02184364
Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT02184052
Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BI 201335 NA in single rising dosesDrug: Placebo
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 50
- Registration Number
- NCT02182297
© Copyright 2025. All Rights Reserved by MedPath